The transcription factor E2F1 controls the GLP-1 receptor pathway in pancreatic β cells.
CP: Metabolism
E2F1
beta cells
glucagon-like peptide 1
insulin secretion
type 2 diabetes
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
09 08 2022
09 08 2022
Historique:
received:
28
04
2021
revised:
11
04
2022
accepted:
15
07
2022
entrez:
10
8
2022
pubmed:
11
8
2022
medline:
13
8
2022
Statut:
ppublish
Résumé
The glucagon-like peptide 1 (Glp-1) has emerged as a hormone with broad pharmacological potential in type 2 diabetes (T2D) treatment, notably by improving β cell functions. The cell-cycle regulator and transcription factor E2f1 is involved in glucose homeostasis by modulating β cell mass and function. Here, we report that β cell-specific genetic ablation of E2f1 (E2f1
Identifiants
pubmed: 35947949
pii: S2211-1247(22)00983-4
doi: 10.1016/j.celrep.2022.111170
pii:
doi:
Substances chimiques
E2F1 Transcription Factor
0
E2F1 protein, human
0
Glucagon-Like Peptide-1 Receptor
0
Insulin
0
Exenatide
9P1872D4OL
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
111170Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.